COVID-19 Treatment Once Administered Via Infusion Is Now Available as Injection

An antibody COVID-19 medication, Sotrovimab—created by GSK and Vir—that originally required administration via infusion can now be given as an intramuscular injection, significantly improving its ease of use. Data from a new study show the drug works just as well at reducing morbidity and mortality among those with mild to moderate cases of COVID-19 in the shot form as it did when administered via infusion. Sotrovimab already has Emergency Use Authorization (EUA) from the United States Food and Drug Administration for the infusion version. GSK and Vir will seek an additional EUA for the drug to be administered via injection. This would allow patients to receive the medication at physician offices, preventing the need for hospital visits. Click here to read more.